This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, presented updated progression-free survival (PFS) and overall survival (OS) results from its completed Phase 1b/2 clinical trial of aldoxorubicin in patients with advanced soft tissue sarcoma (STS). The data were presented as part of CytRx’s Research and Development Day which took place Friday, May 2, 2014 at the Harvard Club in New York City.

Data from the Phase 1b/2 trial demonstrated that aldoxorubicin administered at its maximum tolerated dose (350mg/m 2) showed a substantial increase in median PFS in patients with advanced soft tissue sarcoma (n=13). Partial responses were observed in 5 of 13 patients (38%) and stable disease was observed in 6 of 13 patients (46%). Median PFS of 6.4 months was initially reported at ASCO and ESMO; in the final reported data, observed median PFS had nearly doubled to 11 months, and median OS was 17 months. Notably, following 8 cycles of aldoxorubicin, two patients experienced no progression of disease for 23 and 15 months, respectively, despite no further treatment. Aldoxorubicin was generally well tolerated with no observed cardiotoxicities and no drug-related deaths.

“The data from this now completed study are certainly a promising advance and show that aldoxorubicin was clinically active and generally well tolerated in patients who are particularly difficult to treat given the advanced stage of their disease,” said Sant P. Chawla, M.D., F.R.A.C.P., principal investigator of the trial and renowned sarcoma expert. “There remains a high unmet need for patients with soft tissue sarcoma, especially since many relapse or stop responding to currently available treatments. I am also particularly encouraged by the long progression-free periods experienced by two patients in this study.”

“We are excited to see that the final data showed substantial improvement in median PFS over the previously-reported data, as well as impressive median overall survival. Importantly, the data from the Phase 1b/2 trial came after the administration of only 8 cycles of aldoxorubicin – for future clinical development, we are permitted to dose until progression, which could substantially extend the lives of sarcoma patients. We are actively enrolling patients in our pivotal global Phase 3 clinical trial in second-line STS and we look forward to keeping you updated on our progress,” said Steven A. Kriegsman, CytRx President and Chief Executive Officer. “We would like to thank Dr. Chawla for his tireless work with aldoxorubicin as a novel treatment candidate for sarcoma.”

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 +0.12 0.01%
NASDAQ 4,462.9020 +20.2040 0.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs